Response statement from Sandoz
Due to stability issues impacting the intravenous tuberculosis treatment Rifampicin i.v., we have suspended production of this product. While the company recognizes that it is currently not able to supply the South African market and other markets worldwide with this specific formulation, Sandoz continues to supply Rifampicin in pill form to South African hospitals and healthcare providers. Patients with questions about their specific treatment should speak to a physician or healthcare professional.
Sandoz takes its commitment to patients very seriously and is not compromising on the quality of its products. Helping to eradicate tuberculosis (TB) is a key commitment for the company, and Sandoz is proud to deliver 25% of the anti-TB medicine supply to the WHO. Our medicines reach approximately 500,000 people a year who are living with tuberculosis, helping to make a difference in combatting TB.
Sandoz has been working to urgently identify a new source of Rifampicin i.v. and we hope to be able to provide this important treatment to South African patients again in due time.
